AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28279085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study 29741823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone
Number of subjects: 66
Study 29741823 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide alone
Number of subjects: 66
Study 29741823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus Clofazimine
Number of subjects: 66
Study 29741823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus Thalidomide
Number of subjects: 66
Study 23686894 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinium arctostaphylos fruit hydroalcoholic extract (350 mg capsule every 8 hours for 2 months)
Number of subjects: 40
Study 23686894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22234907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU every four months for 16 months)
Number of subjects: 2378
Study 22234907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2378
Study 20019589 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel Leti 75 mg
Number of subjects: 0
Study 20019589 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel Sanofi (Plavix) 75 mg
Number of subjects: 0
Study 18667923 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive acyclovir therapy
Number of subjects: 67
Study 18667923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16313110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf extract (EGB) 9.6 mg orally, three times per day for three months
Number of subjects: 68
Study 16313110 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (Control group)
Number of subjects: 68
Study 11875324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 151
Study 11875324 — intervention group
Group type: COMPARATOR
Intervention: Amiloride 2.5 + Hydrochlorothiazide 5 mg
Number of subjects: 151
Study 10592130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PKU
Number of subjects: 42
Study 10592130 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 42
Study 10592130 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with PKU <7 years
Number of subjects: 42
Study 8652949 — intervention group
Group type: EXPERIMENTAL
Intervention: Early re-feeding (breast feeding resumed or early re-feeding in non-breast-fed infants within 2-3 days)
Number of subjects: 122
Study 8652949 — intervention group
Group type: COMPARATOR
Intervention: Late re-feeding (return to original feeding pattern after 4-6 days)
Number of subjects: 122
Study 8652949 — intervention group
Group type: EXPERIMENTAL
Intervention: Early re-feeding
Number of subjects: 122
Study 2360135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 0.5 g
Number of subjects: 172
Study 2360135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 1.0 g
Number of subjects: 172
Study 2360135 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 0.25 g
Number of subjects: 172
Study 2360135 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Cefotetan 0.5 g, Cefotetan 1.0 g, Ceftriaxone 0.25 g)
Number of subjects: 172
Study 695661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy
Number of subjects: 451
Study 695661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy initiated at the first missed period or later
Number of subjects: 451
Study 695661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy in the immediate post-ovulatory phase
Number of subjects: 451
Study 695661 — intervention group
Group type: COMPARATOR
Intervention: Overall pregnancies without gestagen therapy
Number of subjects: 451
Study 30860958 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training
Number of subjects: 150
Study 30860958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 26863893 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 58
Study 26863893 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot® White Mineral Trioxide Aggregate (WMTA)
Number of subjects: 58
Study 26863893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempophore™
Number of subjects: 58
Study 26863893 — intervention group
Group type: COMPARATOR
Intervention: ProRoot® WMTA
Number of subjects: 58
Study 25413169 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 17
Study 25413169 — intervention group
Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 17
Study 23482914 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp setting and 370 mgI/mL contrast medium
Number of subjects: 88
Study 23482914 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp setting and 300 mgI/mL contrast medium
Number of subjects: 88
Study 23482914 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp setting and 370 mgI/mL contrast medium
Number of subjects: 88
Study 23482914 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp setting and 300 mgI/mL contrast medium
Number of subjects: 88
Study 23482914 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp setting (both 370 mgI/mL and 300 mgI/mL)
Number of subjects: 88
Study 20553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis (Group A, n = 37)
Number of subjects: 57
Study 20553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic barium enema (Group B, n = 11)
Number of subjects: 57
Study 20553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis and therapeutic barium enema (Group C, n = 9)
Number of subjects: 57
Study 19153029 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules
Number of subjects: 87
Study 19153029 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 87
Study 17302691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned waveform
Number of subjects: 34
Study 17302691 — intervention group
Group type: COMPARATOR
Intervention: 50/50% tilt waveform
Number of subjects: 34
Study 17302691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuned waveform (in patients with DFT >= 15 J)
Number of subjects: 34
Study 17302691 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 34
Study 15049437 — intervention group
Group type: EXPERIMENTAL
Intervention: Solutab tablet (875/125) taken intact or after prior dispersal
Number of subjects: 48
Study 15049437 — intervention group
Group type: COMPARATOR
Intervention: Augmentan film-coated tablet (875/125)
Number of subjects: 48
Study 15049437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (Solutab and Augmentan)
Number of subjects: 48
Study 11426528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (2‐CdA)
Number of subjects: 0
Study 9684058 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 87
Study 9684058 — intervention group
Group type: COMPARATOR
Intervention: NINDS trial endpoint
Number of subjects: 87
Study 8006280 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day of aspirin for 8 days
Number of subjects: 42
Study 8006280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with aspirin)
Number of subjects: 42
Study 8006280 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose aspirin therapy during pacing
Number of subjects: 42
Study 2552802 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinastatin (supplemental)
Number of subjects: 0
Study 2552802 — intervention group
Group type: COMPARATOR
Intervention: Control (cisplatin without urinastatin)
Number of subjects: 0
Study 1107362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 12
Study 1107362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31397931 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 31397931 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate (MPA)
Number of subjects: 0
Study 29058175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668
Study 29058175 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study 25557878 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (test group)
Number of subjects: 0
Study 25557878 — intervention group
Group type: COMPARATOR
Intervention: Delayed loaded implants (control group)
Number of subjects: 0
Study 24435025 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal health record
Number of subjects: 170
Study 24435025 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study 21862415 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered as a 2- to 5-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 103
Study 21862415 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Number of subjects: 103
Study 21862415 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m²) administered on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 103
Study 19860600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch Geriatric Intervention Programme (DGIP)
Number of subjects: 0
Study 18046087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (10 mL/d) in group I
Number of subjects: 41
Study 18046087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fish oil) in group II
Number of subjects: 41
Study 18046087 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children) in group III
Number of subjects: 41
Study 15615766 — intervention group
Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training and bladder training)
Number of subjects: 747
Study 15615766 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 747
Study 14646651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg IV dexamethasone 1 hour before the operation
Number of subjects: 60
Study 14646651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 8 mg IV dexamethasone at the beginning of the operation
Number of subjects: 60
Study 14646651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 8 mg IV dexamethasone 1 hour before the operation, and 24 and 48 hours after the operation
Number of subjects: 60
Study 14646651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 8 mg IV dexamethasone at the beginning of the operation, and 24 and 48 hours after the operation
Number of subjects: 60
Study 14646651 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of 8 mg IV dexamethasone immediately after the operation, and 24 and 48 hours after the operation
Number of subjects: 60
Study 14646651 — intervention group
Group type: COMPARATOR
Intervention: Control, no dexamethasone administration before or after the operation
Number of subjects: 60
Study 10530902 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasion of chorioamniotic plate and amniotic membranes by leukocytes
Number of subjects: 224
Study 10530902 — intervention group
Group type: COMPARATOR
Intervention: Normal chorioamniotic plate and amniotic membranes
Number of subjects: 224
Study 10530902 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasion of chorioamniotic tissues by leukocytes
Number of subjects: 224
Study 7550859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon (IFN) and azidothymidine (AZT)
Number of subjects: 22
Study 7550859 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (IFN-alone group)
Number of subjects: 22
Study 1955549 — intervention group
Group type: EXPERIMENTAL
Intervention: Self migration in sodium hyaluronate (SH)
Number of subjects: 125
Study 1955549 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation and swim up (CS)
Number of subjects: 125
Study 1955549 — intervention group
Group type: COMPARATOR
Intervention: Control (natural intercourse after clomiphene treatment)
Number of subjects: 125
Study 1955549 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI cycles (SH and CS combined)
Number of subjects: 125
Study 7468702 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual exploration of the uterus
Number of subjects: 200
Study 7468702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no manual exploration)
Number of subjects: 200
Study 7468702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (manual exploration and control)
Number of subjects: 200
Study 6151847 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 6151847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 4 weeks
Number of subjects: 183
Study 31307883 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine every 12 weeks
Number of subjects: 183
Study 31307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 4 weeks after cessation
Number of subjects: 183
Study 31307883 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine every 12 weeks after cessation
Number of subjects: 183
Study 31307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in the 4-week group
Number of subjects: 183
Study 31307883 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in the 12-week group
Number of subjects: 183
Study 31307883 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe adverse events in the 4-week group
Number of subjects: 183
Study 31307883 — intervention group
Group type: COMPARATOR
Intervention: Severe adverse events in the 12-week group
Number of subjects: 183
Study 29079475 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐tPNS (1 mA)
Number of subjects: 16
Study 29079475 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 27418817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multicomponent COPD self-management program
Number of subjects: 345
Study 27418817 — intervention group
Group type: COMPARATOR
Intervention: Usual management as per the center's routine practice
Number of subjects: 345
Study 24401721 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 192
Study 24401721 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 192
Study 24401721 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA) with dose >0.18 L/kg/day
Number of subjects: 192
Study 22246943 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol
Number of subjects: 15
Study 22246943 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/timolol
Number of subjects: 15
Study 20465146 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of change in fruit/vegetable consumption
Number of subjects: 700
Study 20465146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 700
Study 20465146 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance
Number of subjects: 700
Study 20465146 — intervention group
Group type: EXPERIMENTAL
Intervention: Processes related to fruit/vegetable consumption
Number of subjects: 700
Study 17350481 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day, titrated to 100 mg TDS)
Number of subjects: 38
Study 17350481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17350481 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 38
Study 15732035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination mycophenolate mofetil and prednisone (MMF-P)
Number of subjects: 17
Study 12783343 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtransducer manometry
Number of subjects: 215
Study 12783343 — intervention group
Group type: COMPARATOR
Intervention: Perfusion manometry
Number of subjects: 215
Study 10561297 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m² IV over 3 hours for eight cycles (24 weeks)
Number of subjects: 209
Study 10561297 — intervention group
Group type: COMPARATOR
Intervention: CMFP combination chemotherapy (cyclophosphamide 100 mg/m²/d orally on days 1 to 14, methotrexate 40 mg/m² IV on days 1 and 8, fluorouracil 600 mg/m² IV on days 1 and 8, and prednisone 40 mg/m²/d orally on days 1 to 14) for six cycles (24 weeks)
Number of subjects: 209
Study 8702043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0
Study 8702043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0
Study 8702043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) and Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Number of subjects: 0
Study 1748064 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ponalrestat once daily for 12 months
Number of subjects: 60
Study 1748064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7077553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamaze classes (n = 22)
Number of subjects: 49
Study 7077553 — intervention group
Group type: COMPARATOR
Intervention: Red Cross parenting classes (n = 7)
Number of subjects: 49
Study 7077553 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Lamaze training (n = 10)
Number of subjects: 49
Study 7077553 — intervention group
Group type: COMPARATOR
Intervention: No training (n = 10)
Number of subjects: 49
Study 7077553 — intervention group
Group type: COMPARATOR
Intervention: Red Cross classes (n = 7)
Number of subjects: 49
Study 31399071 — intervention group
Group type: EXPERIMENTAL
Intervention: ESTEEM intervention (10-session skills-building intervention)
Number of subjects: 0
Study 31399071 — intervention group
Group type: EXPERIMENTAL
Intervention: ESTEEM intervention
Number of subjects: 0
Study 31399071 — intervention group
Group type: COMPARATOR
Intervention: Community mental health treatment and HIV counseling and testing
Number of subjects: 0
Study 28114648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention (telephone-based focusing on weight management, physical activity, and cognitive behavioral pain management)
Number of subjects: 537
Study 28114648 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention (electronic delivery of patient-specific osteoarthritis treatment recommendations)
Number of subjects: 537
Study 28114648 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-provider intervention
Number of subjects: 537
Study 28114648 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 537
Study 26478683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal hybrid-NOTES cholecystectomy (TVC)
Number of subjects: 100
Study 26478683 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study 26478683 — intervention group
Group type: COMPARATOR
Intervention: Needlescopic/3-trocar cholecystectomies (NC)
Number of subjects: 100
Study 23340519 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of methylphenidate hydrochloride (MPH)
Number of subjects: 23
Study 23340519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23340519 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week MPH treatment (follow-up for 7 patients)
Number of subjects: 23
Study 20002693 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative proctocolectomy with ileo-anal anastomosis (IPAA)
Number of subjects: 156
Study 19389209 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion (hemoglobin threshold of 10.0 g per dL)
Number of subjects: 120
Study 19389209 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion (hemoglobin threshold of 8.0 g per dL)
Number of subjects: 120
Study 19389209 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion
Number of subjects: 120
Study 19389209 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion
Number of subjects: 120
Study 17535278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 148
Study 17535278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 14741043 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (20 units/kg of body mass)
Number of subjects: 17
Study 14741043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11339416 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (OCBT) for 2 weeks
Number of subjects: 221
Study 11339416 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT2) for 2 weeks
Number of subjects: 221
Study 11339416 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.i.d., metronidazole 500 mg b.i.d, bismuth subcitrate 240 mg b.i.d. and tetracycline 500 mg b.i.d. (RMBT3) for 3 weeks
Number of subjects: 221
Study 11072531 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN-SR 120 mg
Number of subjects: 38
Study 11072531 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN-SR 120 mg once-daily
Number of subjects: 38
Study 11072531 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN-SR 480 mg a day (4-times-daily)
Number of subjects: 38
Study 11072531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 38
Study 7659429 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 202
Study 7659429 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural opioid analgesia (EOA) with boluses of preservative-free morphine or bupivacaine (1:16% + 2 micrograms/ml fentanyl)
Number of subjects: 202
Study 7659429 — intervention group
Group type: COMPARATOR
Intervention: Various treatments (including anxiolytics)
Number of subjects: 202